-
公开(公告)号：US11680087B2
公开(公告)日：2023-06-20
申请号：US17126712
申请日：2020-12-18
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/05 , C07K14/22 , A61K39/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , C12N7/00 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N2710/20034 , C12N2770/32634 , Y02A50/30
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US10899802B2
公开(公告)日：2021-01-26
申请号：US15728610
申请日：2017-10-10
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/00 , C12N7/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20180022783A1
公开(公告)日：2018-01-25
申请号：US15728610
申请日：2017-10-10
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/39 , A61K39/295 , A61K39/00 , A61K39/12 , A61K39/095 , C12N7/00 , A61K39/13
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US10888611B2
公开(公告)日：2021-01-12
申请号：US15543232
申请日：2016-02-16
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/095 , A61K47/64 , A61K39/00 , C07K14/12 , A61K39/295 , A61K39/12 , A61K39/05 , A61K39/08 , A61K39/04 , C07K14/22 , A61K47/02 , A61K47/22 , A61K47/26
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
Patent Agency Ranking
公开(公告)号：US09822150B2
公开(公告)日：2017-11-21
申请号：US14470922
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/00 , C07K14/22 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00 , A61K39/13 , A61K39/295
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N7/00 , C12N2710/20034 , C12N2770/32634 , Y02A50/466
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20210085773A1
公开(公告)日：2021-03-25
申请号：US17114802
申请日：2020-12-08
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: A61K39/095 , A61K39/00 , C07K14/22 , A61K39/295 , A61K47/64 , A61K39/12 , A61K47/02 , A61K47/22 , A61K47/26
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20180000923A1
公开(公告)日：2018-01-04
申请号：US15543232
申请日：2016-02-16
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20210101943A1
公开(公告)日：2021-04-08
申请号：US17126712
申请日：2020-12-18
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC: C07K14/22 , A61K39/13 , A61K39/295 , A61K39/00 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20150071959A1
公开(公告)日：2015-03-12
申请号：US14470922
申请日：2014-08-27
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
CPC classification number: C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N7/00 , C12N2710/20034 , C12N2770/32634 , Y02A50/466
Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
Abstract translation: 一方面，本发明涉及包含具有SEQ ID NO：1所示序列的第一多肽的组合物和具有SEQ ID NO：2所示序列的第二多肽。在一个实施方案中，组合物包含约120 μg/ ml的包含SEQ ID NO：1所示的氨基酸序列的第一多肽，120μg/ ml的包含SEQ ID NO：2所示的氨基酸序列的第二多肽，约2.8摩尔比的聚山梨醇酯-80 至第一多肽，约2.8摩尔比的聚山梨酯-80至第二多肽，约0.5mg / ml的铝，约10mM的组氨酸和约150mM的氯化钠。 在一个实施方案中，组合物的总剂量为约0.5ml。 在一个实施方案中，组合物的两剂量诱导针对人中不同异源亚家族A和亚科B菌株的杀菌效价。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.016 seconds)
